Cargando…

Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus

Type 2 diabetes is associated with increased risk for the development of cardiovascular disease (CVD) secondary to hyperglycemia’s toxicity to blood vessels. The escalating incidence of CVD among patients with type 2 diabetes has prompted research into how lowering glycated hemoglobin (HbA(1c)) may...

Descripción completa

Detalles Bibliográficos
Autores principales: Palumbo, Pasquale J, Wert, Jonathan M
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828107/
https://www.ncbi.nlm.nih.gov/pubmed/20191079
_version_ 1782177992402796544
author Palumbo, Pasquale J
Wert, Jonathan M
author_facet Palumbo, Pasquale J
Wert, Jonathan M
author_sort Palumbo, Pasquale J
collection PubMed
description Type 2 diabetes is associated with increased risk for the development of cardiovascular disease (CVD) secondary to hyperglycemia’s toxicity to blood vessels. The escalating incidence of CVD among patients with type 2 diabetes has prompted research into how lowering glycated hemoglobin (HbA(1c)) may improve CVD-related morbidity and mortality. Data from recent studies have shown that some patients with type 2 diabetes actually have increased mortality after achieving the lowest possible HbA(1c) using intensive antidiabetes treatment. Multiple factors, such as baseline HbA(1c), duration of diabetes, pancreatic β-cell decline, presence of overweight/obesity, and the pharmacologic durability of antidiabetes medications influence diabetes treatment plans and therapeutic results. Hypertension and dyslipidemia are common comorbidities in patients with type 2 diabetes, which impact the risk of CVD independently of glycemic control. Consideration of all of these risk factors provides the best option for reducing morbidity and mortality in patients with type 2 diabetes. Based on the results of recent trials, the appropriate use of current antidiabetes therapies can optimize glycemic control, but use of intensive glucose-lowering therapy will need to be tailored to individual patient needs and risks.
format Text
id pubmed-2828107
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28281072010-02-26 Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus Palumbo, Pasquale J Wert, Jonathan M Vasc Health Risk Manag Review Type 2 diabetes is associated with increased risk for the development of cardiovascular disease (CVD) secondary to hyperglycemia’s toxicity to blood vessels. The escalating incidence of CVD among patients with type 2 diabetes has prompted research into how lowering glycated hemoglobin (HbA(1c)) may improve CVD-related morbidity and mortality. Data from recent studies have shown that some patients with type 2 diabetes actually have increased mortality after achieving the lowest possible HbA(1c) using intensive antidiabetes treatment. Multiple factors, such as baseline HbA(1c), duration of diabetes, pancreatic β-cell decline, presence of overweight/obesity, and the pharmacologic durability of antidiabetes medications influence diabetes treatment plans and therapeutic results. Hypertension and dyslipidemia are common comorbidities in patients with type 2 diabetes, which impact the risk of CVD independently of glycemic control. Consideration of all of these risk factors provides the best option for reducing morbidity and mortality in patients with type 2 diabetes. Based on the results of recent trials, the appropriate use of current antidiabetes therapies can optimize glycemic control, but use of intensive glucose-lowering therapy will need to be tailored to individual patient needs and risks. Dove Medical Press 2010 2010-02-04 /pmc/articles/PMC2828107/ /pubmed/20191079 Text en © 2010 Palumbo and Wert, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Palumbo, Pasquale J
Wert, Jonathan M
Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus
title Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus
title_full Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus
title_fullStr Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus
title_full_unstemmed Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus
title_short Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus
title_sort impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828107/
https://www.ncbi.nlm.nih.gov/pubmed/20191079
work_keys_str_mv AT palumbopasqualej impactofdatafromrecentclinicaltrialsonstrategiesfortreatingpatientswithtype2diabetesmellitus
AT wertjonathanm impactofdatafromrecentclinicaltrialsonstrategiesfortreatingpatientswithtype2diabetesmellitus